Author Profile

Taiho Gets First FDA Nod for All-Oral AML Regimen
The treatment will be available to newly-diagnosed patients who are ineligible to receive intensive induction chemotherapy or aged 75 years or older. read more
Makary Resigns as FDA Head
According to AP News, Makary resigned under pressure from HHS Secretary Robert Kennedy Jr. and the decision was backed by the White House. read more
FDA Warns of Blood Cancer Risk with Tazverik Tablets
When approved, the incidence rate for SPMs was 1.7%, but a phase 3 trial this year found the risk of SPMs to be 5.7%. read more
Angelini to Buy Catalyst for $4.1B, Entering U.S. Market
The acquisition will give Angelini Pharma the oral drug Firdapse, the only FDA approved treatment for LEMS. read more
CellCentric Raises $220M Series D to Advance Multiple Myeloma Pill
The funds will help advance inobrodib, a first-in-class p300/CBP inhibitor with a completed a phase 2 study. read more
FDA Advisory Panel Votes Against AstraZeneca Oral Breast Cancer Med
The Oncologic Drugs Advisory Committee failed to reach a majority vote in favor of the benefit–risk profile of AstraZeneca's camizestrant. read more
Cytokinetics Looks to Expand Heart Drug into Non-Obstructive HCM
Already approved for obstructive HCM, Cytokinetics announced positive topline results from a phase 3 trial of aficamten in non-obstructive HCM. read more
Novartis to Close German Tablets and Capsules Site
The drugmaker will cut 220 jobs as part of the planned closure of a production site by the end of 2028. read more
Arvinas Breast Cancer Nod Marks First FDA PROTAC Approval
Veppanu reduced disease progression and death by 43% compared to fulvestrant. read more
Novartis Finalizes U.S. Expansion Plan With Seventh New Facility
The facility will focus on manufacturing APIs for solid dosage tablets and capsules as part of a plan to produce all key medicines within the country. read more
J&J to Market Four Drugs on TrumpRx
The drugs include metformin, metformin extended release, Invokana (an SGLT2 inhibitor for type 2 diabetes) and blockbuster Xarelto (a blood thinner). read more
Lilly Pens $2.3B Deal for Ajax, Picking Up Oral Blood Cancer Candidate
Ajax's lead candidate is an oral, Type II JAK2 inhibitor that uses a unique mode of binding for potentially deeper and more durable disease control. read more
FDA Approves Merck Once-Daily HIV Pill
Idvynso demonstrated non-inferior efficacy compared to the three-drug regimen in a phase 3 trial. read more
Novo to Seek Approval of Oral GLP-1s to Treat T2 Diabetes in Kids
If approved, the drug will be the first oral GLP-1 RA that provides superior glycemic efficacy in pediatric patients with T2 diabetes. read more
Trump Signs Order to Fast Track Psychedelic Drugs for Mental Health Treatment
Three psychedelic drugs will receive national priority vouchers from the FDA next week. read more
BioAge Oral Inflammation Drug Cuts Heart Risks in Trial
The phase 1 trial led to median hsCRP reductions of more than 85% when patients took daily doses. read more
Kailera Sets IPO Record, Raising $625M for Obesity Drugs
Among its most promising drugs is oral ribupatide, a once-daily pill entering phase 3 trials in China. read more
Dr. Erica Schwartz Nominated as New CDC Director
Schwartz, an ex deputy surgeon general, will take over the role if she receives Senate approval, which could take months. read more
Travere Gets Landmark FDA Approval in Rare Kidney Disease
The FDA has granted full approval to Filspari to reduce proteinuria in focal segmental glomerulosclerosis without nephrotic syndrome. read more
Peptide-to-Small-Molecule Translation
Recent advances are turning what was once a trial-and-error exercise into a disciplined and reproducible design workflow. read more

May/June 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Tablets & Capsules

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!